Skip NavigationSkip to Content
Return Return to Search Results

Race-specific prostate cancer outcomes in a cohort of military health care beneficiaries undergoing surgery: 1990-2017

  1. Author:
    Oehrlein, Nathan
    Streicher, Samantha A [ORCID]
    Kuo, Huai-Ching
    Chaurasia, Avinash
    McFadden, Jacob
    Nousome,Darryl
    Chen, Yongmei [ORCID]
    Stroup, Sean P
    Musser, John
    Brand, Timothy
    Porter, Christopher
    Rosner, Inger L
    Chesnut, Gregory T
    Onofaro, Kayla C [ORCID]
    Rebbeck, Timothy R [ORCID]
    D'Amico, Anthony
    Lu-Yao, Grace [ORCID]
    Cullen, Jennifer [ORCID]

  2. Author Address

    Urology Service, Department of Surgery, Walter Reed National Military Medical Center, Bethesda, Maryland, USA., Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA., The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA., Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA., Department of Radiation Oncology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA., Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland, USA., Eli Lilly and Company, Indianapolis, Indiana, USA., Department of Urology, Naval Medical Center San Diego, San Diego, California, USA., Tripler Army Medical Center, Honolulu, Hawaii, USA., Madigan Army Medical Center, Tacoma, WA, USA., Virginia Mason Medical Center, Seattle, WA, USA., Department of Medical Oncology, Sidney Kimmel Cancer Center at Jefferson, Sidney Kimmel Medical College, Philadelphia, Pennsylvania, USA., INOVA, Falls Church, Virginia, USA., Division of Population Sciences, Dana Farber Cancer Institute and Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, Massachusetts, USA., Department of Radiation Oncology, Brigham and Women 39;s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Sidney Kimmel Cancer Center at Jefferson, Philadelphia, Pennsylvania, USA., Jefferson College of Population Health, Philadelphia, Pennsylvania, USA., Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, USA., Case Comprehensive Cancer Center, Cleveland, Ohio, USA.,
    1. Year: 2022
    2. Date: May 31
    3. Epub Date: 2022 05 31
  2. Journal: Cancer Medicine
  4. Type of Article: Article
  1. Abstract:

    There is substantial variability in prostate cancer (PCa) mortality rates across Caucasian American (CA), African American (AA), Asian, and Hispanic men; however, these estimates are unable to disentangle race or ethnicity from confounding factors. The current study explores survival differences in long-term PCa outcomes between self-reported AA and CA men, and examines clinicopathologic features across self-reported CA, AA, Asian, and Hispanic men. This retrospective cohort study utilized the Center for Prostate Disease Research (CPDR) Multi-center National Database from 1990 to 2017. Subjects were consented at military treatment facilities nationwide. AA, CA, Asian, or Hispanic men who underwent radical prostatectomy (RP) for localized PCa within the first year of diagnosis were included in the analyses. Time from RP to biochemical recurrence (BCR), BCR to metastasis, and metastasis to overall death were evaluated using Kaplan-Meier unadjusted estimation curves and adjusted Cox proportional hazards regression. This study included 7067 men, of whom 5155 (73%) were CA, 1468 (21%) were AA, 237 (3%) were Asian, and 207 (3%) were Hispanic. AA men had a significantly decreased time from RP to BCR compared to CA men (HR = 1.25, 95% CI = 1.06-1.48, p = 0.01); however, no difference was observed between AA and CA men for a time from BCR to metastasis (HR = 0.73, 95% CI = 0.39-1.33, p = 0.302) and time from metastasis to overall death (HR = 0.67, 95% CI = 0.36-1.26, p = 0.213). In an equal access health care setting, AA men had a shorter survival time from RP to BCR, but comparable survival time from BCR to metastasis and metastasis to overall death. © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1002/cam4.4787
  3. PMID: 35638719

Library Notes

  1. Fiscal Year: FY2021-2022
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel